Hua Medicine-B (02552) to Review FY2025 Results and Final Dividend Proposal on 26 March 2026

Bulletin Express

03/16

Hua Medicine-B (stock code: 02552) has scheduled a board meeting for 26 March 2026 (Thursday), according to a filing with The Stock Exchange of Hong Kong Limited dated 16 March 2026.

The agenda includes: 1. Approval of the audited financial results for the year ended 31 December 2025. 2. Consideration of a final dividend recommendation, if any. 3. Discussion of other routine corporate matters.

The board currently consists of three executive directors (Dr. Li Chen, Mr. George Chien Cheng Lin and Dr. Yi Zhang), one non-executive director (Mr. Robert Taylor Nelsen) and three independent non-executive directors (Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung).

The company will release its FY2025 results after board approval, providing shareholders with detailed financial information and any dividend decision.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1185329206"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1185329206\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1185329206?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185329206","market":"us","top_or_hot":-1,"title":"Hua Medicine-B (02552) to Review FY2025 Results and Final Dividend Proposal on 26 March 2026","media":"Bulletin Express","content":"<p>Hua Medicine-B (stock code: 02552) has scheduled a board meeting for 26 March 2026 (Thursday), according to a filing with The Stock Exchange of Hong Kong Limited dated 16 March 2026.</p>\n<p>The agenda includes:\n1. Approval of the audited financial results for the year ended 31 December 2025.\n2. Consideration of a final dividend recommendation, if any.\n3. Discussion of other routine corporate matters.</p>\n<p>The board currently consists of three executive directors (Dr. Li Chen, Mr. George Chien Cheng Lin and Dr. Yi Zhang), one non-executive director (Mr. Robert Taylor Nelsen) and three independent non-executive directors (Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung).</p>\n<p>The company will release its FY2025 results after board approval, providing shareholders with detailed financial information and any dividend decision.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hua Medicine-B (02552) to Review FY2025 Results and Final Dividend Proposal on 26 March 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHua Medicine-B (02552) to Review FY2025 Results and Final Dividend Proposal on 26 March 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-16 16:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hua Medicine-B (stock code: 02552) has scheduled a board meeting for 26 March 2026 (Thursday), according to a filing with The Stock Exchange of Hong Kong Limited dated 16 March 2026.</p>\n<p>The agenda includes:\n1. Approval of the audited financial results for the year ended 31 December 2025.\n2. Consideration of a final dividend recommendation, if any.\n3. Discussion of other routine corporate matters.</p>\n<p>The board currently consists of three executive directors (Dr. Li Chen, Mr. George Chien Cheng Lin and Dr. Yi Zhang), one non-executive director (Mr. Robert Taylor Nelsen) and three independent non-executive directors (Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung).</p>\n<p>The company will release its FY2025 results after board approval, providing shareholders with detailed financial information and any dividend decision.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02552","symbol_name":"华领医药-B","start_time":0,"source_url":"","article_id":"1185329206","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185329206","pubTimestamp":1773650435,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hua Medicine-B (stock code: 02552) has scheduled a board meeting for 26 March 2026 (Thursday), according to a filing with The Stock Exchange of Hong Kong Limited dated 16 March 2026. The agenda...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02552":"华领医药-B"},"translate_title":"华领医药-B(02552)将于2026年3月26日审阅2025财年业绩及末期股息建议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02552":1},"content_text":"Hua Medicine-B (stock code: 02552) has scheduled a board meeting for 26 March 2026 (Thursday), according to a filing with The Stock Exchange of Hong Kong Limited dated 16 March 2026.\nThe agenda includes:\n1. Approval of the audited financial results for the year ended 31 December 2025.\n2. Consideration of a final dividend recommendation, if any.\n3. Discussion of other routine corporate matters.\nThe board currently consists of three executive directors (Dr. Li Chen, Mr. George Chien Cheng Lin and Dr. Yi Zhang), one non-executive director (Mr. Robert Taylor Nelsen) and three independent non-executive directors (Mr. William Robert Keller, Mr. Yiu Wa Alec Tsui and Mr. Yiu Leung Andy Cheung).\nThe company will release its FY2025 results after board approval, providing shareholders with detailed financial information and any dividend decision.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}